TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28776077
Drug: Novel formulation
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel formulation of abiraterone acetate (100 mg in fasted state)
Study: 28776077
Drug: Novel formulation
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel formulation of abiraterone acetate (200 mg in fasted state)
Study: 28776077
Drug: Novel formulation
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel formulation of abiraterone acetate (200 mg in fed state)
Study: 28776077
Drug: Novel formulation
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel formulation of abiraterone acetate
Study: 28776077
Drug: Zytiga (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zytiga (1000 mg)
Study: 21703101
Drug: Intranasal carbon
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal carbon dioxide (CO(2))
Study: 21703101
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (no CO(2))
Study: 1291203
Drug: Formula-fed with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula-fed with supplementary zinc 1.14-2.28 mg/kg/d
Study: 6439639
Drug: Hyperosmolar basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperosmolar basic nutrition solution (3% amino acids, carbohydrates and electrolytes, 806 mosm/l)
Study: 6439639
Drug: Isoosmolar electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoosmolar electrolyte solution (299 mosm/l)
Study: 29528793
Drug: Fruquintinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib (5 mg once daily in 4-week cycles of 3 weeks on, 1 week off)
Study: 25312546
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group receiving feedback regarding assessment results and recommendations for subsequent treatment.
Study: 25312546
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving treatment as usual and global feedback regarding assessment results without recommendations.
Study: 21243280
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no massage therapy)
Study: 18456137
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded OMIs (up to 250 g of direct force applied immediately)
Study: 17080220
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment for glycaemic control
Study: 10030506
Drug: Electronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic treatment suggestions for heart failure, ischemic heart disease, reactive airways disease, and uncomplicated hypertension.
Study: 10030506
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no access to electronic treatment suggestions).
Study: 7554309
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter)
Study: 2256971
Drug: One-injection-site peribulbar
Normalized name: Gel-One Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-injection-site peribulbar anesthesia
Study: 29945252
Drug: L-AmB 10
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-AmB 10 mg/kg on day 1 (single dose)
Study: 29945252
Drug: L-AmB 10
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-AmB 10 mg/kg on day 1 and 5 mg/kg on day 3 (2 doses)
Study: 29945252
Drug: L-AmB 10
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-AmB 10 mg/kg on day 1 and 5 mg/kg on days 3 and 7 (3 doses)
Study: 29945252
Drug: L-AmB 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-AmB 3 mg/kg/day for 14 days (control)
Study: 26360284
Drug: D-serine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-serine (60 mg/kg) given orally in divided daily doses for 16 weeks
Study: 17304425
Drug: 5 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg/d enteral iron polymaltose complex (IPC) at 2 weeks of age
Study: 17304425
Drug: 5 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg/d enteral iron polymaltose complex (IPC) at 4 weeks of age
Study: 10206032
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of 1% hyperbaric bupivacaine injected over 40 sec (Group SLOW)
Study: 10206032
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of 1% hyperbaric bupivacaine injected over 3 sec (Group FAST)
Study: 2129376
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg anisoylated plasminogen streptokinase activator complex (BRL 26921)
Study: 520990
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg daily etiroxate hydrochloride
Study: 520990
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg daily etiroxate hydrochloride
Study: 31755625
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment - on target (below 130 mm Hg)
Study: 31755625
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment - on target (below 140 mm Hg)
Study: 31755625
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment - on target
Study: 26509147
Drug: CE model
Normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE model with treatment effect
Study: 24624861
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl (normal saline solution)
Study: 18024876
Drug: Neoadjuvant cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant cisplatin chemotherapy (NACT) before radiotherapy (RT) or chemoradiotherapy (CRT)
Study: 18024876
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by RT or CRT
Study: 10499382
Drug: Hypnosedation (hypnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosedation (hypnosis in combination with conscious IV sedation and local anaesthesia)
Study: 8877349
Drug: Prednisolone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (2 mg/kg/day)
Study: 8877349
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/kg/day)
Study: 1496699
Drug: Chloroquine base
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine base 25 mg/kg
Study: 1496699
Drug: Amodiaquine base
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine base 25 mg/kg
Study: 29520872
Drug: peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2a 180 μg/wk × 48 weeks (group 4)
Study: 29520872
Drug: peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2a 90 μg/wk × 24 weeks (group 1)
Study: 29520872
Drug: peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2a 90 μg/wk × 48 weeks (group 3)
Study: 29520872
Drug: peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2a 180 μg/wk × 24 weeks (group 2)
Study: 24738461
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin + 5 mg solifenacin (mild obstruction symptom group)
Study: 24738461
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin (mild obstruction symptom group)
Study: 24738461
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin + 5 mg solifenacin (moderate obstruction symptom group)
Study: 24738461
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin (moderate obstruction symptom group)
Study: 10469854
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg/d) treated hemodialysis patients (+ACEi)
Study: 22452841
Drug: OTC preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC preparations (overall)
Study: 22452841
Drug: 4% lidocaine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine-containing preparations
Study: 17565490
Drug: 1-week triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week triple therapy with rabeprazole 10 mg b.i.d., amoxicillin 750 mg b.i.d., and metronidazole 250 mg b.i.d. (RAM)
Study: 17565490
Drug: 2-week dual
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week dual therapy with rabeprazole 10 mg q.i.d. and amoxicillin 500 mg q.i.d. (RA)
Study: 12111046
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy combined with Dietary Intervention (HRT+DIET)
Study: 10621764
Drug: Emergency telephone
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency telephone support in addition to treatment as usual (intervention group)
Study: 6729651
Drug: High-dose weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose weekly fractionation regimen
Study: 6729651
Drug: Conventional daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional daily fractionation schedule
Study: 24343275
Drug: Microencapsulated sodium
Normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microencapsulated sodium butyrate (MSB) 300 mg daily
Study: 19938151
Drug: Hcy‐lowering therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hcy‐lowering therapy (5 mg folate and 1500 microg vitamin B(12) daily)
Study: 19938151
Drug: Alpha‐lipoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha‐lipoic acid (alpha‐LA) therapy (1200 mg daily)
Study: 7872875
Drug: selegiline hydrochloride
Normalized name: Selegiline Hydrochloride
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selegiline hydrochloride (10 mg/d)
Study: 2219469
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Mycobacterium vaccae (10^9 irradiation‐killed M. vaccae)
Study: 7746913
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Mycobacterium vaccae
Study: 660709
Drug: Anti-tuberculosis drugs
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculosis drugs and oral iron
Study: 660709
Drug: Anti-tuberculosis drugs
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculosis drugs only
Study: 31618176
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of concurrent aerobic (60‐80% heart rate reserve) and resistance (40‐65% of 1RM) training
Study: 27748083
Drug: Peficitinib 25
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 25 mg plus MTX
Study: 27748083
Drug: Peficitinib 50
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 50 mg plus MTX
Study: 27748083
Drug: Peficitinib 100
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 100 mg plus MTX
Study: 27748083
Drug: Peficitinib 150
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 150 mg plus MTX
Study: 23482645
Drug: HIV DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV DNA vaccine (4 mg) coding for clade B Gag, Pol, and Nef and clade A, B, and C Env, followed by a replication-deficient adenovirus type 5 boost (10^10 particle units)
Study: 21490144
Drug: Phenylbutyrate administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutyrate administration
Study: 21490144
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation during phenylbutyrate therapy
Study: 19551673
Drug: Fixed Combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Combination (FC) therapy as second choice
Study: 19551673
Drug: Fixed Combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Combination (FC) therapy as third choice
Study: 19551673
Drug: Fixed Combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Combination (FC) therapy as first choice
Study: 19551673
Drug: FC therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FC therapy overall
Study: 19551673
Drug: Prostaglandins dosing
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandins dosing time
Study: 16710082
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (target INR 2-3)
Study: 15451902
Drug: AS‐3201 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS‐3201 at 5 mg/day
Study: 15451902
Drug: AS‐3201 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS‐3201 at 20 mg/day
Study: 3073270
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon, type alpha (IFN) ointment, 7,000 Ul/gm
Study: 17118480
Drug: Gliclazide treatment
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide treatment for 8 weeks
Study: 15001324
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of etanercept 25 mg (subcutaneously twice a week) and oral methotrexate (up to 20 mg every week)
Study: 18050208
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of etanercept and methotrexate
Study: 11368288
Drug: Intravenous amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amifostine 910 mg/m2
Study: 11368288
Drug: Intravenous amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amifostine 200 mg/m2
Study: 11368288
Drug: Intravenous amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amifostine 340 mg/m2
Study: 11368288
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (cisplatin 100 mg/m2 and cyclophosphamide 1000 mg/m2)
Study: 7934153
Drug: Inhaled ipratropium
Normalized name: ipratropium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ipratropium bromide (4 puffs of 0.02 mg)
Study: 7934153
Drug: Intramuscular atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular atropine (0.5 mg)
Study: 3351153
Drug: Indecainide 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indecainide 50 mg three times daily
Study: 3351153
Drug: Indecainide 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indecainide 75 mg three times daily
Study: 3351153
Drug: Indecainide 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indecainide 100 mg three times daily
Study: 28966223
Drug: 12-week lifestyle
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week lifestyle modifications (combination of aerobic exercise training and dietary modification)
Study: 28489239
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate solution
Study: 23245290
Drug: 100 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/m2 cisplatin once every 3 weeks (arm A)
Study: 23245290
Drug: 40 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 cisplatin once per week (arm B)
Study: 10936467
Drug: Capecitabine at
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at a dose of 2.510 mg/m²/day (divided into two equal doses) given in an intermittent schedule (2 weeks on/1 week off)
Study: 12959305
Drug: Fenoterol dry
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol dry powder capsules (DPC) 0.2 mg, 0.4 mg
Study: 12959305
Drug: Fenoterol metered
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol metered dose inhaler (MDI) 0.2 mg, 0.4 mg
Study: 12959305
Drug: Cumulative doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative doses of fenoterol DPC (0.2, 0.6, 1.4, 3.0, 6.2 mg)
Study: 12959305
Drug: Cumulative doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative doses of fenoterol MDI (0.2, 0.6, 1.4, 3.0, 6.2 mg)
Study: 3320307
Drug: Vincristine (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (0.025 mg/kg intravenously for eight dosages over 12 weeks)
Study: 3320307
Drug: OKT3 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 monoclonal antibody (first 2 weeks after transplantation)
Study: 26937948
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous unfractionated heparin (5000-10000 units/day) until postoperative day 7 (POD7)
Study: 26937948
Drug: Ablative surgery
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative surgery and neck dissection without heparin
Study: 24747805
Drug: Ozone (0.30ppm)
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone (0.30ppm) inhalation during 1 hour of exercise
Study: 24378268
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg/day for one month
Study: 18828077
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NBI pit pattern and VPI
Study: 17273672
Drug: Colchicine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.5 mg/day)
Study: 17273672
Drug: Prednisone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.75 mg/kg/day)
Study: 8637698
Drug: Single oral-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral-dose azithromycin (20 mg/kg)
Study: 8637698
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline eye ointment for 6 weeks
Study: 4025792
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural anesthesia with 12-15 ml 0.25% plain bupivacaine and general anesthesia (flunitrazepam 1.5-2 mg, pancuronium bromide 0.1 mg/kg)
Study: 4025792
Drug: Neuroleptanaesthesia (droperidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptanaesthesia (droperidol 0.1-0.2 mg/kg, fentanyl 0.01 mg/kg, pancuronium bromide 0.1 mg/kg, thiopentone 100-150 mg)
Study: 30452422
Drug: Edasalonexent (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edasalonexent (100 mg/kg/day)
Study: 29461363
Drug: 60 mm
Normalized name: Koromex Diaphragm Coil 60 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mm Hg capsule pressure
Study: 29461363
Drug: 70 mm
Normalized name: ostomy supply 70 mm MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mm Hg capsule pressure
Study: 29461363
Drug: 80 mm
Normalized name: Koromex Coil Diaphragm 80 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mm Hg capsule pressure
Study: 29461363
Drug: 90 mm
Normalized name: ostomy supply 90 mm MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mm Hg capsule pressure
Study: 29461363
Drug: 100 mm
Normalized name: Tenscare Electrode Pads 50x100 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mm Hg capsule pressure
Study: 26043861
Drug: 6 servings
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 servings (96 g) of WG wheat
Study: 26043861
Drug: 3 servings
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 servings (48 g) of WG wheat
Study: 25461966
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) used as an adjunct to endodontic re-treatment
Study: 25461966
Drug: Endodontic re-treatment
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic re-treatment alone
Study: 19771507
Drug: Twice-weekly strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly strength training
Study: 19753741
Drug: Microdermabrasion treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdermabrasion treatments (six sessions of aluminum oxide microdermabrasion spaced over 7 to 10-day intervals)
Study: 19753741
Drug: Microdermabrasion treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdermabrasion treatments (six sessions)
Study: 7553254
Drug: Bromocriptine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2 x 2.5 mg/d for 14 days)
Study: 7553254
Drug: Metergoline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline (3 x 4 mg/d for 10 days)
Study: 7000139
Drug: Photochemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photochemotherapy with oral 8‐MOP followed by UV‐A (PUVA)